Slide 1: 4Q22 Earnings Presentation
4Q22 Earnings Presentation February 14, 2023
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: 4Q '22 Financial Results
4Q ‘22 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights* Decline* -15% Margin* -630bps Growth* -34% Continuing Ops. Adjusted Revenue: $741 million; -28% y/y • Organic: -23%; M&A 0%; FX -5% • Non-COVID: +8% organic growth 36% 64% DX DAS • COVID: $31 million vs. $3
Slide 4: 2022 Financial Results
2022 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights* Decline* -11% Margin* -500bps Growth* -30% Continuing Ops. Adjusted Revenue: $3.3 billion; -13% y/y • Organic: -18%; M&A 9%; FX -4% • Non-COVID: +9% organic growth 44% 56% DX DAS • COVID: $617 million vs. $1.
Slide 5: Discovery & Analytical Solutions
DISCOVERY & ANALYTICAL SOLUTIONS 4Q22 Performance Food • +9% Con’t Ops reported growth Con't Ops ✓ Pharma up +DD, Academic +HSD Life • Organic: +13%, M&A: 0%, FX: -4% Sciences ✓ Strong +DD growth across reagents, instrumentation, & software • +6% Combined* growth Ind/Env $0.7B • Organic: +11%; M&A:
Slide 6: Diagnostics
DIAGNOSTICS 4Q22 Performance Applied Reproductive ✓ -LSD organic, birth pressures in Asia & Genomics • -44% reported decline Health Americas ImmunoDx • Organic: -39%; M&A: +0%; FX: -5% • Non-COVID organic revenue +4% • +MSD ex. China ImmunoDx ✓ -DD organic driven by COVID declines y/y & China lockdo
Slide 7: Financial Guidance
FINANCIAL GUIDANCE 2023 Guidance* • Con’t Ops Adj. Revenue: $2.94 billion; -11% reported • Organic: -11%; M&A +0%; FX 0% • Non-COVID Organic: +9% • COVID: $0 million (vs. $617 million in 2022) • 30% adj. operating margin • ~$90 million of net Interest expense, other • ~20% adj. tax rate • Adj. EPS:
Slide 8: Innovating for a healthier world
INNOVATING for a healthier world Steve Willoughby | Senior Vice President, Investor Relations | steve.willoughby@perkinelmer.com | @PerkinElmerIR 8